Pharmacovigilance [Pharmacovigilance update].

Details

Serval ID
serval:BIB_12B1E6FE7B5D
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Title
Pharmacovigilance [Pharmacovigilance update].
Journal
Revue Médicale Suisse
Author(s)
Diezi L., Renard D., Rothuizen L.E., Livio F.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
2014
Volume
10
Number
412-413
Pages
119-122
Language
french
Notes
Publication types: English Abstract ; Journal Article ; Review Publication Status: ppublishPublication Type English Abstract. Journal Article. Review.
Abstract
The main pharmacovigilance updates in 2013 are reviewed. Nitrofurantoin: lower efficacy and an increased risk of adverse events when creatinine clearance is below 60 ml/min. Dabigatran: contraindicated in patients with mechanical heart valves. Azithromycin: QT prolongation and increased risk of death. Zolpidem: towards a lower dosage. Roflumilast: avoid in patients known or at risk for mood disorders. Retigabine: indication restricted to last-line use and new monitoring requirements after reports of pigment changes in retina and other tissues. Telaprevir and rituximab: severe mucocutaneous reactions. Fingolimod: rare cases of progressive multifocal leucoencephalopathy. Tolvaptan: potential for hepatotoxicity. Nicotinic acid/laropiprant: suspension of marketing authorization as benefits no longer outweigh risks.
Keywords
Aminopyridines/adverse effects, Antibodies, Monoclonal, Murine-Derived/adverse effects, Azithromycin/adverse effects, Benzamides/adverse effects, Carbamates/adverse effects, Cyclopropanes/adverse effects, Humans, Nitrofurantoin/adverse effects, Oligopeptides/adverse effects, Pharmacovigilance, Phenylenediamines/adverse effects, Pyridines/adverse effects
Pubmed
Create date
25/05/2014 15:01
Last modification date
20/08/2019 12:40
Usage data